Management of a cohort of Sri Lankan women with antiphospholipid syndrome (APLS) and recurrent pregnancy loss

Show simple item record

dc.contributor.author Gunawardane, P.T.K.
dc.contributor.author Wijeyaratne, C.N.
dc.contributor.author Dodampahala, S.H.
dc.contributor.author Jayawardane, D.B.I.A.
dc.contributor.author Tudawe, M.
dc.contributor.author Seneviratne, S.L.
dc.date.accessioned 2011-10-07T05:00:32Z
dc.date.available 2011-10-07T05:00:32Z
dc.date.issued 2006
dc.identifier.citation Sri Lanka College of Obstetricians & Gynaecologists, 39th annual scientific sessions, 2006 en_US
dc.identifier.uri http://archive.cmb.ac.lk:8080/xmlui/handle/70130/282
dc.description.abstract BACKGROUND: APLS is an autoimmune disease leading to recurrent pregnancy loss, the laboratory diagnosis being limited in Sri Lanka. OBJECTIVE: We report the management outcomes of a series of affected women from a single tertiary care unit. DESIGN: Observational case study DIAGNOSTIC CRITERIA: International consensus guidelines for APLS (1999). OUTCOME MEASURES: Outcome of the last pregnancy managed with subcutaneous heparin and aspirin (international practice guidelines) versus previous obstetric outcome of pregnancies that did not receive treatment. RESULTS: 70 with APLS; 38(54 percent) pregnant when recruited. Mean age 31.4ñ5.7 years, duration since marriage 6.1ñ3.5 years. Number of children: 0.44ñ0.67 per woman, 46(66 percent) childless, 17(24 percent) one child, none with 2or>. Total gestations 316, mean gestations 4.5ñ2.1 per patient (range 1-13). Previous pregnancy outcomes: 33(10.4 percent) live births, 18(5.7 percent) stillbirths, 227(71.8 percent) abortions - 87 late (>10 weeks), 140 early (<10 weeks); 21 had 3 or > early miscarriages. Lupus anticoagulant/DRWT positive 25, KCT positive 14, Anticardiolipin antibodies positive 8, ANF positive 4, dsDNA positive 2. Of 15 tested in a reference laboratory AnnexinV IgG+ 2,IgM+ 3 ; anti-_2-Glycoprotein 1 IgG+ 4 ;IgM+ 2 ; Phosphatidyliositol + 12, Phosphatidylethanlamine + 5, Phosphatidylserine +12. Co-morbidities: pregnancy hypertension 11(15.7 percent), gestational diabetes 13(18.5 percent), cerebrovascular disease 3(4.2 percent), deep vein thrombosis 4(5.7 percent). Family history: 25(35 percent) hypertension; 29(41 percent) diabetes, 10(15 percent) recurrent abortions, 1 recurrent stillbriths. 49 pregnancies received heparin and aspirin. Outcomes specific treatment (49) versus no previous treatment (267): early miscarriage 2(4 percent) vs. 138(51.6 percent) (p=0.0001), late abortion 10(20 percent) vs. 77(28.8 percent) (p=0.08), still birth 0 vs. 18(6.7 percent) (p=0.001), live birth 25(53 percent) vs. 9(3 percent) (p=0.0001). In treatment group 14(56 percent) normal delivery; 9(36 percent) elective LSCS; 2(8 percent) emergency LSCS, average birth weight of 2.6 ñ 0.56 kg (range 1.25-3.96) with a mean period of gestation of 36.2ñ2.6 weeks. 12(24 percent) gestations on treatment are currently pregnant with no fetal growth restriction after 28 weeks. CONCLUSIONS AND RECOMMENDATIONS: APLS presenting with recurrent fetal losses requires a high degree of suspicion and management by a multidisciplinary team, which considerably improves the chances of a live birth. en_US
dc.language.iso en en_US
dc.subject APLS en_US
dc.subject recurrent pregnancy loss en_US
dc.title Management of a cohort of Sri Lankan women with antiphospholipid syndrome (APLS) and recurrent pregnancy loss en_US
dc.type Research paper en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account